Loading clinical trials...
Loading clinical trials...
Evaluating the Efficacy of Bipolar Androgen Therapy in Extending Metastasis-free Survival in Patients With M0 Castrate-resistant Prostate Cancer With PSA Progression But Not Radiological or Clinical Progression on Darolutamide
Conditions
Interventions
Testosterone Enanthate
Locations
12
Australia
The Canberra Hospital
Garran, Australian Capital Territory, Australia
The Border Cancer Hospital
Albury, New South Wales, Australia
St Vincents Hospital
Darlinghurst, New South Wales, Australia
GenesisCare North Shore
St Leonards, New South Wales, Australia
Sydney Adventist Hospital
Wahroonga, New South Wales, Australia
ICON Cancer Centre
Chermside, Queensland, Australia
Start Date
August 14, 2024
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2028
Last Updated
April 24, 2026
NCT06257264
NCT03620786
NCT04693377
NCT05424783
NCT06190899
NCT02706561
Lead Sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions